|| List of recent Factor-related patents
|Secure digital download storage device|
A secure usb flash drive employing digital rights management to implement secure digital media storage such as that provided by encrypted storage utilizing content protection for recordable media (cprm) or the like. Unlike a secure digital card which provides such protection, it does not need an sd card port which is cprm enabled, or alternatively a reader adapted for use therewith.
|Factorial hidden markov models estimation device, method, and program|
An approximate computation unit computes an approximate of a determinant of a hessian matrix relating to a parameter of an observation model represented as a linear combination of parameters determined by each layer 1 latent variable of factorial hidden markov models. A variational probability computation unit computes a variational probability of a latent variable using the approximate of the determinant.
|Method for controlling rpm of construction machine engine|
According to the present disclosure, there is provided a method for controlling an rpm of an engine of construction machinery, including and converting and setting the received load factor to a load variation rate; receiving a current load factor of the engine and converting the received current load factor of the engine to a load variation rate; controlling driving of the engine with a corrected rpm, which is obtained by decreasing the rpm of the engine by a predetermined rate from a preset rpm when the current load factor of the engine and the load variation rate according to the current load factor are equal to or smaller than a predetermined rate of the predetermined load factor of the engine and a predetermined rate of the load variation rate for a first time, respectively; and controlling continuously decreasing the corrected rpm to a predetermined rate or smaller, when the current load factor of the engine and the load variation rate according to the current load factor are equal to or smaller than the predetermined rate of the predetermined load factor of the engine and the predetermined rate of the load variation rate for a second time, respectively.. .
|Devices and systems to mitigate traumatic brain and other injuries caused by concussive or blast forces|
A system for reducing the damaging effects of radiant energy, blast, or concussive events includes applying pressure to at least one jugular vein to reduce the egress of blood from the cranial cavity during or before the incidence of the imparting event. Reducing blood outflow from the cranial cavity increases intracranial volume and/or pressure of the cerebrospinal fluid to reduce the risk of traumatic brain injury and injuries to the spinal column.
|Circumferential aerosol device|
The present application discloses devices and methods for delivering a therapeutic compound to the olfactory epithelium of an animal or human. The device having one or more channels for imparting a circumferential and axial velocity to the discharged fluid, and an outlet that discharges an aerosol spray having a circumferential and axial velocity as it enters the nasal cavity of a user.
|Synthetic matrix for controlled cell ingrowth and tissue regeneration|
Biomaterials containing a three-dimensional polymeric network formed from the reaction of a composition containing at least a first synthetic precursor molecule having n nucleophilic groups and a second precursor molecule having m electrophilic groups wherein the sum of n+m is at least five and wherein the sum of the weights of the first and second precursor molecules is in a range from about 8 to about 16% b weight of the composition, preferably from about 10 to about 15%, more preferably from about 12 to about 14.5% by weight of the composition. In one embodiment, the first and second precursor molecules are polyethylene glycols functionalized with nucleophilic and electrophilic groups, respectively.
|Macrocycles as factor xia inhibitors|
Or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.
|Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases|
A phytosphingosine derivative of chemical formula ia or ib, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like..
|Compositions and methods for inhibiting expression of factor vii gene|
The invention relates to a double-stranded ribonucleic acid (dsrna) for inhibiting the expression of the factor vii gene.. .
|Small molecule modulators of epigenetic regulation and their therapeutic applications|
Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific dna promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (mef2), the forkhead/winged helix transcription factor foxp3 and the transcription factor gata3.
|Compositions and methods for inhibition of mmp:mmp-substrate interactions|
The present invention provides compounds for disrupting the binding of a matrix metalloprotease (mmp) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the mmp's ability to cleave a substrate protein.
|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|
The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, victoza (liraglutide), tresiba (insulin degludec), ryzodeg (insulin degludec/insulin aspart), ideglira (liraglutide and insulin degludec), novoseven (recombinant human coagulation factor viia), novoseven rt (recombinant human coagulation factor viia), or turoctocog alfa (third-generation recombinant coagulation factor viii)..
|Functional cell surface display of ligands for the insulin and/or insulin growth factor 1 receptor and applications thereof|
Systems for making, identifying, and selecting recombinant cells that express a ligand for the insulin receptor (ir) or insulin growth factor i (igf-1) receptor are described. In general, libraries of recombinant cells are constructed that are capable of displaying a plurality of ligand molecules on the cell surface.
Method of providing notification messages on a bar form factor display device operating at low power, the bar form factor display device comprising front and back major faces, the front major face arranged to present a first display screen and the back major face arranged to present a second display screen different to the first display screen, wherein the second display screen is a bi-stable display screen, comprising the steps of: i) executing software on the device, the software operating the device in a low power notification mode in which the first display screen is off and in which the device is operable to receive a notification message; ii) the software on the device receiving a notification message; iii) displaying the notification message on the bi-stable display screen.. .
|Apparatus and method for embedding components in small-form-factor, system-on-packages|
According to various aspects of the present disclosure, devices and methods are disclosed that include communication platform including a small form factor platform having a system-on-package architecture. The system-on-package architecture may be arranged as a stack of layers including: a first layer of the stack of layers having a first conformable material; a second layer of the stack of layers having a second conformable material; a third layer of the stack of layers having a third material, wherein the first conformable material and the second conformable material are more flexible than the third material; and one or more electronic components embedded within the stack of layers, wherein the one or more electronic components are configured to process a received wireless signal..
|Vascular endothelial growth factor 2|
Disclosed are human vegf-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies.
The invention relates to a method for the reclassification of a subject to a more appropriate risk assessment to that obtained using the algorithms for such risk estimation such us but not limited to framingham, regicor, score, procamor qrisk based on the presence of different polymorphisms. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for cvd as well as computer-implemented means for carrying out said method..
|Functionalized nanoparticles for intracellular delivery of biologically active molecules|
Functionalized biocompatible nanoparticles capable of penetrating through a mammalian cell membrane and delivering intracellularly a plurality of bioactive molecules for modulating a cellular function are disclosed herein the functionalized biocompatible nanoparticles comprise: a central nanoparticle ranging in size from about 5 to about 50 nm and having a polymer coating thereon, a plurality of functional groups covalently attached to the polymer coating, wherein the plurality of bioactive molecules are attached to the plurality of the functional groups, and wherein the plurality of bioactive molecules include at least a peptide and a protein, and wherein the peptide is capable of penetrating through the mammalian cell membrane and entering into the cell, and wherein the protein is capable of providing a new functionality within the cell. The protein may be a transcription factor selected from the group consisting of oct4, sox2, nanog, lin28, cmyc, and klf4..
|Method to induce neovascular formation and tissue regeneration|
The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (vegf), or that encodes a polypeptide comprising an active site of the vegf. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte.
|Method for egfr directed combination treatment of cancer|
The present invention relates to a method of treating patients suffering from cancers driven by deregulated human epidermal growth factor receptor (her/human egfr), wherein an irreversible tyrosine kinase inhibitor (tki) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mab is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.. .
|Methods of treating cancer|
Methods of treating cancers comprising fgfr1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (fgfr1) extracellular domain (ecd) and/or an fgfr1 ecd fusion molecule.
|Novel complex mutations in the epidermal growth factor receptor kinase domain|
New mutations were found in exon 19 of the egfr gene, the exon that is often mutated in tumors. The invention comprises methods of detecting the mutations, methods of prognosis and methods of predicting response to treatment based on the presence of absence of the mutations..
|Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients|
The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, gammagard liquid (an immune globulin infusion (human)); advate (antihemophilic factor (recombinant), plasma/albumin-free method, (rahf)); bax 111 (vonicog alfa, or [618-threonine,709-aspartic acid] von willebrand factor homo sapiens (1381a>t,1472h>d variant)); or an adeno-associated viral vector containing a liver-specific human factor ix expression cassette, e.g., sscaav2/8-lp1-hfixco..
|Dressing material with cell components for wound healing|
There is provided a dressing for treating a wound. The dressing for healing a wound can be useful in maintaining a moisture environment at a wound site using a biocompatible polymer scaffold, and effectively promoting healing of a wound by various growth factors secreted by skin cells or stem cells attached to the biocompatible polymer scaffold as well..
|Crest factor reduction for band-limited multi-carrier signals|
A crest factor reduction (cfr) circuit reduces the peak-to-average (par) power of a digitally modulated signal in a complex baseband is achieved by post-processing the input signal, with negligible increase in out-of-band emissions. The cfr circuit takes advantage of a procedure that solves for an optimum cfr using a constraint-optimization approach.
|Enlarged substrate for magnetic recording medium|
An enlarged substrate for a magnetic recording medium used in a data storage device such as a hard disc drive (hdd). In some embodiments, an apparatus includes a substrate for a magnetic recording disc for installation in a 3½ inch form factor hard disc drive, the substrate having an overall diameter of nominally from 96.9 mm to 100.4 mm.
|Explosive device and mini depth charge grenade|
An explosive device contains a water-reactive material that ignites upon exposure to water. The water-reactive material ignites a water-activated fuse that has a predetermined burn rate and length.
|Risk assessment for industrial systems using big data|
A cloud-based risk assessment service collects industrial data from multiple relevant and connected sources for storage and analysis on a cloud platform. The service analyzes gathered data from internal and external sources and customers across different industries to identify operational trends as a function of industry type, application type, equipment in use, device configurations, and other such variables.
|Estimation of q-factor in time domain|
A method can include receiving seismic traces associated with a geologic environment; determining time domain stretch values for individual wavelets in at least a portion of the seismic traces with respect to a spatial dimension of the geologic environment; and estimating at least one q-factor value for at least a portion of the geologic environment via a comparison of the time domain stretch values to a q-factor model.. .
|Extracellular matrix (ecm) structures for tissue regeneration|
An extracellular matrix (ecm) structure for tissue regeneration, the ecm structure having a a sheet member comprising small intestine submucosa (sis), the sis sheet member being folded and laminated proximate the sheet member edge, wherein a folded laminated ecm structure having a cavity therein is formed, the ecm structure further including an ecm composition that is disposed in the ecm structure cavity, the ecm composition including liver basement membrane, urinary bladder submucosa, a mesenchymal stem cell and a growth factor.. .
|Method for obtaining sterile human amniotic fluid and uses thereof|
Provided herein is a pre-caesarean method for collecting amniotic fluid from a patient. A needle is inserted into the incision site for the future c-section, which may be under ultrasound guidance, through which the amniotic fluid is drawn under a low level suction and, optionally, gravity to a sterile collection container.
|Sirna molecule for inhibiting growth of melanin and application thereof|
Provided is a double-chain sirna molecule targeting a microphthalmia-associated transcription factor mitf coding gene. A sense strand of the sirna molecule has a sequence of seq id no: 3 and an anti-sense strand has a sequence of seq id no: 4, and the anti-sense strand specifically binds to mrna of the mitf coding gene, to degrade the mrna, thereby reducing the systhesis of melanin.
|Process for preparing heparinoids and intermediates useful in the synthesis thereof|
Processes are disclosed for the synthesis of the factor xa anticoagulant fondaparinux and related compounds. Protected pentasaccharide intermediates and efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions are provided..
|Genetic factors in blood pressure|
The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension..
|Targeting the egfr-sglt1 interaction for cancer therapy|
A compound can destabilize a binding interaction between an epidermal growth factor receptor (egfr) and a sodium/glucose co-transporter 1 (sglt 1). In one embodiment, the compound is a peptide derived from the interacting domain of egfr.
|Compounds, compositions and methods for the treatment of diseases through inhibiting tgf-ß activity|
The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting the activity of the transforming growth factor beta (tgf-β). More specifically, the disclosed compounds, compositions and methods are useful in the treatment of certain cancers (e.g.
|Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome|
The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
|Novel 3,3-diethyl-alkyl-2-oxa-spiro[4.5]dec-7-enes and their use in perfume compositions|
The present invention is directed to novel 3,3-diethyl-alkyl-2-oxa-spiro[4.5]dec-7-ene compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of these novel compounds.. .
|Novel diethyl-methyl-hexahydro-isobenzofurans and their use in perfume compositions|
The present invention is directed to novel diethyl-methyl-hexahydro-isobenzofuran compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of these novel compounds.. .
|Genetic markers for macular degeneration disorder treatment|
Provided in part herein are genetic variations (e.g., single nucleotide polymorphisms) associated with a vascular endothelial growth factor (vegf) suppression response to an anti-vegf agent for treatment of a macular degeneration disorder (e.g., age-related macular degeneration (amd)). Also provided herein are methods for determining a genotype that includes such genetic variations, methods for predicting a vegf suppression response for a subject according to a genotype, and methods for selecting a treatment suitable for treating a macular degeneration disorder (e.g., wet amd) for a subject in need thereof according to a genotype..
|Method and apparatus for managing measurement event trigger criteria|
A method for a user equipment (ue) to manage measurement event trigger criteria including determining a first pathloss for a serving cell and a second pathloss for at least one neighbor cell; adjusting the measurement event trigger criteria based on at least one of the determined first pathloss, the determined second pathloss and a weight factor x received from the serving cell; and triggering a measurement event based on the adjusted measurement event trigger criteria.. .
|Defined systems for epithelial cell culture and use thereof|
The present invention provides cell culture media formulations which support the in vitro cultivation of animal epithelial cells. The media comprise at least one fibroblast growth factor (fgf) and at least one agent that induces increased intracellular camp levels, and optionally comprise ascorbic acid.
|Devices and methods for determining the risk of developing a serious infection|
A device for calculating risk of a patient developing a serious infection, the device comprising: a controller; storage storing electronic program instructions for controlling the controller; a display for displaying a user interface; and input means; wherein the controller is operable, under control of the electronic program instructions, to: receive input via the input means, the input comprising one or more values representing respective measures of one or more risk factors associated with biological sample(s) obtained from the patient; process the input to calculate the risk; and display an indication of the calculated risk via the display.. .
|Dosage forms of apixaban|
The present invention relates to a factor xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form.. .
|Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material, and method for forming bone|
Provided is a growth factor anchoring type bone graft material, wherein a bone graft substrate exposing at least a collagen fiber is bound to a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide. The same can be produced by mixing a bone graft substrate and a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide, and is also superior in osteogenic ability..
|Nanobodies against tumor necrosis factor-alpha|
The present invention relates to improved nanobodies™ against tumor necrosis factor-alpha (tnf-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such nanobodies. The invention also relates to nucleic acids encoding such nanobodies and polypeptides; to methods for preparing such nanobodies and polypeptides; to host cells expressing or capable of expressing such nanobodies or polypeptides; to compositions comprising such nanobodies, polypeptides, nucleic acids or host cells; and to uses of such nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes..
|Humanized monoclonal antibodies to hepatocyte growth factor|
The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. .
|Composition exhibiting a von willebrand factor (vwf) protease activity comprising a polypeptide chain with the amino acid sequence aaggilhlellv|
The invention relates to vwf cleaving entities having a molecular weight of 180 kd, 170 kd, 160 kd, 120 kd or 110 kd and an n-terminal amino acid sequence of aaggilhlellv, vwf cleaving complexes and methods for their production.. .
|Human skin equivalents expressing exogenous polypeptides|
The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides.
|Supplemented oil compositions and methods for improved health|
Disclosed are compositions and methods comprising supplemented oils for improving health, reducing cardiovascular risk factors, or treating certain conditions.. .